Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 24 2025
0mins
Source: Benzinga
Matthew Zorn's New Role: Attorney Matthew Zorn, known for his advocacy in cannabis and psychedelics policy, has been appointed as Deputy General Counsel at the U.S. Department of Health and Human Services, focusing on psychedelics policy, marking a significant shift from litigation to federal policymaking.
Impact on Psychedelics Research: Zorn's appointment is expected to enhance support for psychedelic-assisted therapy, particularly for veterans, as the new administration prioritizes exploring the therapeutic potential of psychedelics, with recent statements from the FDA and VA indicating positive outcomes from related studies.
Analyst Views on MNMD
Wall Street analysts forecast MNMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MNMD is 28.25 USD with a low forecast of 18.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 15.020
Low
18.00
Averages
28.25
High
55.00
Current: 15.020
Low
18.00
Averages
28.25
High
55.00
About MNMD
Definium Therapeutics, Inc., formerly Mind Medicine (MindMed) Inc., is engaged in developing therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. The Company plans to advance DT1201 ODT toward FDA submissions in the two largest psychiatric markets, generalized anxiety disorder (GAD) and major depressive disorder (MDD). Its late-stage pipeline includes four Phase 3 trials, two each for GAD and MDD, anchored by its lead candidate, DT120 ODT, which has received an FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is engaged in advancing its commercial strategy and operational readiness to support a care model and prepare for the launch of DT120 ODT, if approved and marketed. It also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
